Physician profile
David Crouch
NPI 1932150430
$15,694.86
in general payments reported to CMS, 2019-2025
70 companies · $2,078 in 2025
The $2,078 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,028 · 2020: $1,691 · 2021: $2,630 · 2022: $2,358 · 2023: $2,395 · 2024: $2,515 · 2025: $2,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,987.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,227.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,125.37 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,640.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,147.29 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $1,092.52 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $836.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.34 | 2019-2024 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $492.48 | 2019-2025 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.75 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $340.16 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $324.09 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $242.73 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $240.85 | 2019-2022 | |
| Allergan, INC. | $232.93 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $216.77 | 2021-2025 | Gvoke Hypopen |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Crouch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.